Journal of pancreatology最新文献_第4页

Mass Spectrometry-based Proteomics Technology in Pancreatic Cancer Research 基于质谱的蛋白质组学技术在胰腺癌研究中的应用

Journal of pancreatology Pub Date : 2023-11-14 DOI: 10.1097/jp9.0000000000000152

Xue Sun, Siyuan Wang, Catherine C.L. Wong

引用次数: 0

Retrospective review paper identification racial disparities in patients with pancreatic cancer 回顾性研究论文确定胰腺癌患者的种族差异

Journal of pancreatology Pub Date : 2023-11-02 DOI: 10.1097/jp9.0000000000000151

Chibueze Onyemkpa, Danielle Dougherty, Sajjaad Samat, Tolutope Oyasiji, Michael McLeod

{"title":"Retrospective review paper identification racial disparities in patients with pancreatic cancer","authors":"Chibueze Onyemkpa, Danielle Dougherty, Sajjaad Samat, Tolutope Oyasiji, Michael McLeod","doi":"10.1097/jp9.0000000000000151","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000151","url":null,"abstract":"Background: Pancreatic cancer is the fourth leading cause of cancer death in the US. There has been postulates of racial disparities. Based on this, we primarily examined the presence of race, for the diagnosis and treatment of pancreatic cancer. Methods: A retrospective review was conducted on patients with pancreatic cancers using the Surveillance Epidemiology, and End Results - Medicare registry. Univariate and multivariate analyses were performed. Overall Survival analysis was done using the Kaplan-Meier curve. Comparison of survival curves was done using the log rank test. Cox proportional hazards regression model was used to determine independent predictors of survival. Other areas focused on were Time interval from diagnosis to treatment”, “Predictors of Surgery of the primary site”, “Predictors for recommending surgery of the primary site”, “Predictors for oncologic resection”, “Predictors of performance and refusal of surgery of primary site if recommended”, and “Predictors for any other therapy (all therapies excluding surgery). Results: A total of 52,951 patients were identified from the database. 24, 523 were males and 26, 715 were females. 81.9% were Caucasian, 10.9% were black and 7.2% were other races. There was approximately equal distribution of the different stages between both genders. 10.2% of the females were diagnosed at stage I, 28.9%, 9.3% and 51.6% at stages I, Ill and IV respectively compared to males with 8.4% 28.3%, 9.2% and 54.1% for stages I, II, Ill and IV respectively. 9.5% of the black patients were diagnosed at stage I, 24.2% at stage II, 10.1% at stage III and 56.2% at stage IV. A similar distribution was noted in the other races. Black patients had worse overall survival when compared to Caucasians (p=0.004) and other races (p = 0.001). Conclusion: Compared to Caucasian patients, black patients with pancreatic cancer had worse overall survival.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"9 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135875709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Ethnicity on the Outcomes of Acute Pancreatitis: Insights from USNational Inpatient Sample 种族对急性胰腺炎结局的影响:来自美国全国住院患者样本的见解

Journal of pancreatology Pub Date : 2023-10-30 DOI: 10.1097/jp9.0000000000000149

Ali Jaan, Sheza Malik, Joel E. McFarland, Erik T. Olson, Byron Cryer

引用次数: 0

Computed tomography-based delta-radiomics of tumor core_edge combination for systemic treatment response evaluation in pancreatic cancer 基于计算机断层扫描的肿瘤核心边缘组合的δ放射组学用于胰腺癌的全身治疗反应评估

Journal of pancreatology Pub Date : 2023-10-30 DOI: 10.1097/jp9.0000000000000148

Xiang Li, Na Lu, Peijun Hu, Yiwen Chen, Liying Liu, Xinyuan Liu, Chengxiang Guo, Wenbo Xiao, Ke Sun, Jingsong Li, Xueli Bai, Tingbo Liang

{"title":"Computed tomography-based delta-radiomics of tumor core_edge combination for systemic treatment response evaluation in pancreatic cancer","authors":"Xiang Li, Na Lu, Peijun Hu, Yiwen Chen, Liying Liu, Xinyuan Liu, Chengxiang Guo, Wenbo Xiao, Ke Sun, Jingsong Li, Xueli Bai, Tingbo Liang","doi":"10.1097/jp9.0000000000000148","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000148","url":null,"abstract":"Background: As a systemic disease, pancreatic cancer (PC) can be treated systemically to raise the R 0 resection rate and enhance patient prognosis. The best ways to assess the treatment response to systemic treatment of patients with PC are still lacking. Methods: A total of 122 PC patients were enrolled; 25 of these patients were used as an independent testing set. According to the pathologic response, PC patients were classified into the responder and non-responder groups. The whole tumor, core, edge, and peritumoral were segmented from the enhanced CT images. Machine learning models were created by extracting the variations in radionics features before and after therapy (delta radiomics features). Finally, we compared the performance of models based on radiomics features, changes in tumor markers, and radiologic evaluation. Results: The model based on the core (Area under Curve, AUC=0.864) and edge features (AUC=0.853) showed better performance than that based on the whole tumor (AUC=0.847) or peritumoral area (AUC=0.846). Moreover, the tumor core_edge combination model (AUC=0.899) could better increase confidence in treatment response than using either of them alone. The accuracies of models based on changes in tumor markers and radiologic evaluation were relatively poorer than of the radiomics model. Moreover, Patients predicted to respond to therapy using the radiomics model showed a relatively longer overall survival (43 months vs 27 months), although there were no significant differences (p=0.063). Conclusions: The tumor core_edge combination delta radiomics model is an effective approach to evaluate pathologic response in PC patients with systemic treatment.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136107045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of interventional therapy via hepatic artery in pancreatic neuroendocrine neoplasms liver metastases 经肝动脉介入治疗在胰腺神经内分泌肿瘤肝转移中的应用

Journal of pancreatology Pub Date : 2023-10-27 DOI: 10.1097/jp9.0000000000000150

Haikuan Liu, Hang Yu, Dequan Yang, Wang Yao, Yu Wang

引用次数: 0

Genetic alterations and tumor mutation burden predict chemosensitivity of pancreatic cancer: a retrospective study 遗传改变和肿瘤突变负荷预测胰腺癌的化疗敏感性:一项回顾性研究

Journal of pancreatology Pub Date : 2023-10-27 DOI: 10.1097/jp9.0000000000000147

Manyi Hu, Yiting Xu, Yangyang Wang, Cao Chen, Junjun He, Ke Sun, Qi Zhang, Tingbo Liang

{"title":"Genetic alterations and tumor mutation burden predict chemosensitivity of pancreatic cancer: a retrospective study","authors":"Manyi Hu, Yiting Xu, Yangyang Wang, Cao Chen, Junjun He, Ke Sun, Qi Zhang, Tingbo Liang","doi":"10.1097/jp9.0000000000000147","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000147","url":null,"abstract":"Background: Chemotherapy stands as a recommended approach for all stages of pancreatic cancer. However, its efficacy stratification remains obscure. Genomic sequencing is extensively applied across diverse diseases. This study aims to explore the potential genomic markers in relation to the decision-making of chemotherapy. Methods: A total of 140 patients with pancreatic cancer were categorized into chemotherapy-first group and adjuvant chemotherapy group. The genomic alterations were detected from the next-generation sequencing using surgical or fine-needle-biopsy specimens. Chemotherapy response was defined according to objective response based on the RECIST criteria (version 1.1). Results: In the chemotherapy-first group, the patients who harbored higher TMB levels had significant shorter PFS than that with low TMB levels (Hazard ratio [HR] = 30.362, P = 0.002). No independent risk factors were found to be correlated with chemoresistance in patients receiving chemotherapy at first (all P > 0.05). In the adjuvant chemotherapy group, the increased CA125 level of more than 35 U/mL potentially elucidated a shorter period of DFS (HR = 3.695, P = 0.020). Conclusion: Our study indicated that a high level of TMB may predict earlier tumor progression in pancreatic cancer patients received chemotherapy at first. The elevation of CA125 presents itself as a predictive indicator for postoperative chemotherapy patients' tumor recurrence, whereas gene mutations remain unrelated to this phenomenon.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136234223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: Diagnostic and Therapeutic Implications 胰腺导管腺癌的代谢特征:诊断和治疗意义

Journal of pancreatology Pub Date : 2023-10-21 DOI: 10.1097/jp9.0000000000000146

Ruining Gong, Yonglu Hu, Qian Yu, Lin Fang, He Ren

引用次数: 0

Initial chemotherapy option for Pancreatic ductal adenocarcinoma in patients with adequate performance status 表现良好的胰腺导管腺癌患者的初始化疗选择

Journal of pancreatology Pub Date : 2023-09-27 DOI: 10.1097/jp9.0000000000000144

Jiazhang Xing, Yuping Ge, Xiaolei Gong, Yuan Liu, Yuejuan Cheng

{"title":"Initial chemotherapy option for Pancreatic ductal adenocarcinoma in patients with adequate performance status","authors":"Jiazhang Xing, Yuping Ge, Xiaolei Gong, Yuan Liu, Yuejuan Cheng","doi":"10.1097/jp9.0000000000000144","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000144","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a highly progressive lethal malignancy, with chemotherapy being the primary treatment modality. This article provides a review of the initial chemotherapy options for PDAC patients with adequate performance status, comparing FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) or modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NabP) regimens. The availability of limited evidence from randomized trials restricts a direct comparison between the two regimens. Based on our review, (m)FOLFIRINOX yields superior survival outcomes compared to GEM-NabP in metastatic PDAC. For locally advanced PDAC, either (m)FOLFIRINOX or GEM-NabP can be considered initial chemotherapy. In the neoadjuvant setting for borderline resectable PDAC, both regimens have demonstrated promising results in achieving feasible resection rates. However, mFOLFIRINOX remains the preferred choice for adjuvant chemotherapy. The selection of initial chemotherapy for PDAC depends on the disease stage, patients' performance status, and tumor molecular alterations. Further research and clinical trials are necessary to optimize treatment approaches for PDAC patients.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135477065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

THE ROLE OF PREDICTIVE AND PROGNOSTIC VALUES OF INFLAMMATORY MARKERS IN ACUTE PANCREATITIS: A NARRATIVE REVIEW 急性胰腺炎炎症标志物的预测和预后价值的作用:一个叙述性的回顾

Journal of pancreatology Pub Date : 2023-09-27 DOI: 10.1097/jp9.0000000000000145

Saira Rafaqat, Aqsa Sattar, Farhan Anjum, Mahrukh Gilani, Sana Rafaqat

{"title":"THE ROLE OF PREDICTIVE AND PROGNOSTIC VALUES OF INFLAMMATORY MARKERS IN ACUTE PANCREATITIS: A NARRATIVE REVIEW","authors":"Saira Rafaqat, Aqsa Sattar, Farhan Anjum, Mahrukh Gilani, Sana Rafaqat","doi":"10.1097/jp9.0000000000000145","DOIUrl":"https://doi.org/10.1097/jp9.0000000000000145","url":null,"abstract":"Pancreatitis is an inflammatory condition affecting the pancreas and is classified into two types, acute and chronic, which can manifest in various forms. This review article summarizes the role of predictive and prognostic values of inflammatory markers in the pathogenesis of acute pancreatitis, mainly focused on preclinical and clinical studies. It includes serum amyloid A, monocyte chemotactic protein-1, erythrocyte sedimentation rate, interleukin-6(IL-6), C-reactive protein, interleukin 10(IL-10), myeloperoxidase, pentraxin 3 and plasminogen activator inhibitor 1. SAA3 plays a crucial role in developing acute pancreatitis by triggering a receptor-interacting protein 3-dependent necroptosis pathway in acinar cells. Targeting SAA3 could be a potential strategy for treating acute pancreatitis. The recruitment of monocytes/macrophages and the activation of the systemic monocyte chemotactic protein-1 (MCP-1) signaling pathway play a role in the progression of pancreatitis, and blocking MCP-1 may have a suppressive effect on the development of pancreatic fibrosis. The erythrocyte sedimentation rate (ESR) can predict severe acute pancreatitis with slightly lower accuracy than C-reactive protein (CRP). When ESR and CRP levels are combined at 24 hours, they predict severe acute pancreatitis accurately. IL-6 plays a crucial role in activating the Janus kinase/signal transducers and activators of the transcription pathway, exacerbating pancreatitis and contributing to the initiation and progression of pancreatic cancer. Endogenous interleukin-10 plays a crucial role in controlling the regenerative phase and limiting the severity of fibrosis and glandular atrophy induced by repeated episodes of acute pancreatitis in mice. The predictive and diagnostic roles of these inflammatory factors in pancreatitis were introduced in detail in this review.","PeriodicalId":92925,"journal":{"name":"Journal of pancreatology","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135477063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platinum-based chemotherapy for metastatic insulinoma harboring germline mutation in DNA damage repair pathway: A case report 铂基化疗治疗DNA损伤修复途径中携带种系突变的转移性胰岛素瘤:1例报告

Journal of pancreatology Pub Date : 2023-09-20 DOI: 10.1097/jp9.0000000000000143

Kaili Yang, Hongyan Ying, Mei Guan, Lina Wang, Jia Xu, Yuejuan Cheng

引用次数: 0